Paris, March 14th, 2011 – Deinove (Alternext Paris: ALDEI), the world's leading specialist in Deinococcus
bacteria for biofuels, green chemistry and antibiotics, today announced that its Antibiotics Expert
Committee had met recently to analyze the antibiotic screening results for the company's collection of
The Expert Committee is dedicated to the Deinobiotics project and is composed of four members with
acknowledged experience in antibiotics discovery and the prevention and treatment of infectious
- Professor Pierre Dellamonica, Head of the Infectious Disease Department at Nice University
Hospital, a member of the Steering Committee for the French National Plan for the Prevention of
Hospital-Acquired Infections and an expert advisor to the Eurobiomed cluster's Strategic Projects
- Professor Vincent Jarlier, Head of the Medical Bacteriology Department at Pitié-Salpêtrière
University Hospital, Paris.
- Dr Dominique Le Beller, former Director of Operations at Novexel and a former Head of Anti-
infective Biochemistry at Aventis.
- Dr Jean-Pierre Tafani, founder of APcis (animal models of infectious diseases), diplomate of the
European College of Vet Pharmacology and Toxicology, at Maisons-Alfort, recipient of Siemens
Innovation Trophy Award in 2006 and a former Director of Animal Health Research at British
Petroleum Animal Nutrition.
Deinove CEO Jacques Biton emphasized "we are delighted and honoured to have such renowned
experts advising us on the Deinobiotics project. The Expert Committee considered that our results were
encouraging and confirmed the relevance of our approach based on screening a bacterial biodiversity
inexplored so far, since the conventional approaches over the last ten years have been very
disappointing. Along with our partners, we have moved back to the fundamentals of antibiotic discovery
and hope to identify novel, innovative molecules that protect patients against multiresistant infections -
a real public health issue."
In order to identify novel compounds, Deinove and its partners have screened several thousands of
bacteria from the company's proprietary collection. This primary screening phase revealed that several
Deinove's rare bacteria produce antibacterial and/or antifungal antibiotic activities. These activities may
be due to novel compounds, which in turn could provide innovative solutions in the treatment of
infectious diseases that are increasingly resistant to conventional antibiotics.
Several candidate molecules are undergoing preliminary evaluation in in vitro assays and activity tests
with numerous hospital-acquired bacteria that are particularly resistant to today's standard antibiotics.
The discovery strategy adopted by Deinove is seeking to rapidly generate at least one antibacterial or
antifungal drug candidate (a "lead"), elucidate its molecular structure, determine its mode of action and
biological target and check its efficacy in animals, with a view to subsequent regulatory and toxicology
preclinical trials and clinical trials in man (that could be performed by a pharma partner).
Deinove's antibiotics discovery operations have attracted a total of €1.1 million in public financial
support from a variety of sources: Oseo (the French state innovation agency), the Languedoc-Roussillon
Regional Council and the European Regional Development Fund (ERDF). The projects have also been
accredited by the Eurobiomed cluster. The consortium comprises Deinove (the project leader), the
Nîmes-based biotech start-up Nosopharm (a specialist in antibiotic screening), the CPBS (a joint CNRS-
University of Montpellier 1 lab for pathogenic agent studies) and the Institute of Structural Genomics
Infectious diseases remain the leading cause of death worldwide1. Each year, nosocomial (hospital-acquired)
infections affect around 2 million people in the USA2 and 5 million in the European Union3, with a mortality rate of
5% (i.e. around 285,000 deaths annually). The global antibacterials market was worth $30 billion in 2006 and is set
to grow to $45 billion by 20124. There is an urgent need to develop a new therapeutic arsenal, in view of the
resurgence of bacterial multi-resistance in community and nosocomial infections, which is particularly critical for
infections caused by Gram-negative bacteria (for eg. E. Coli which is the main responsible bacteria of urinary
infections), and of the emergence of new pathogens. Rare, robust bacteria in general and Deinococcus sp. in
particular have been rarely studied and under-exploited to date - despite the fact that (alike the rare
Actinomycetes) they could constitute one of the most productive bacterial reservoirs of novel antibiotics.
The greentech company Deinove (Alternext Paris: ALDEI) is dedicated to the development and commercial
exploitation of innovative technological processes for the production of biofuels and other compounds of
industrial or pharmaceutical interest, by exploiting the deinococci's exceptional natural properties. Deinove
successfully floated on the Alternext stock market in April 2010. The company intends to leverage its proprietary
bacterial strains, technologies and processes by outlicensing to industrial partners. Deinove has partnered with
leading sugar, ethanol and starch company TEREOS in order to develop the Deinol project, which aims at producing
cellulosic ethanol in existing industrial facilities.
Deinove currently has 25 staff and operates several collaborative R&D programmes with the CNRS (Montpellier
and Marseilles), the University of Paris V, INSA Toulouse and the VTT-Technical Research Centre of Finland. It was
incorporated in late 2006 under the joint impetus of Philippe Pouletty MD (Managing Partner at the private equity
firm Truffle Capital) and Professor Miroslav Radman (Professor of Cell Biology at Paris-Descartes University, a
member of the French Academy of Science and winner of the 2003 INSERM Medical Research Prize). Professor
Radman elucidated the genetic mechanism behind the extraordinary natural properties of the bacterium
Deinococcus (biodiversity and robustness) on which Deinove's innovation strategy is based. The company’s
headquarters are in Paris and it operates a lab in Montpellier (Cap Alpha Technopark), southern France.
This press release and the information contained herein do not constitute an offer to sell or subscribe to, or a
solicitation of an offer to buy or subscribe to, shares in Deinove ("the Company") in any country. This press release
contains forward-looking statements that relate to the Company’s objectives. Such forward-looking statements are
based solely on the current expectations and assumptions of the Company’s management and involve risk and
uncertainties. Potential risks and uncertainties include, without limitation, whether the Company will be successful
in implementing its strategies, whether there will be continued growth in the relevant market and demand for the
Company’s products, new products or technological developments introduced by competitors, and risks associated
with managing growth. Unfavorable developments in connection with these and other risks and uncertainties
described, in particular, in Chapter 4 of the Company’s prospectus prepared in connection with its IPO and on which
the French Autorité des Marches Financiers (“AMF”) granted its visa no. 10-014 on March 25 2010, could cause the
Company to fail to achieve the objectives expressed by the forward-looking statements above.
Updates are available on the company's website http://www.deinove.com
Communication agency C
Tel.: +33 142 68 86 43 / +33 664 18 99 59 T
Angelita de Francisco
COO and Strategic Marketing
Tel.: +33 142 03 27 32 / +33 607 15 28 87